Pharma intermediates · API · CDMO

From a 200 L pilot line, to a 8,000 L production reactor.

We develop processes for pharmaceutical intermediates and APIs, and we run them: route development, pilot scale-up, technology transfer. The kilogram-scale validation is ours, and so is the commercial order above 100 kg — one line, end to end, no second supplier in the middle.

First conversation is free · NDA in place before structures are exchanged

Zhonghongda production hall: reactors and pipework along the service corridor
Production hall · reactors and pipe corridor
  • 14 unitsPilot reactors, 200–500 L
  • ≤ 9.5 MPaHydrogenation pressure ceiling
  • 8,000 LSingle-reactor capacity
  • 13 typesReaction classes accepted

01 Company

A company whose main business is scale-up.

Nanjing Zhonghongda Pharmaceutical Technology Co., Ltd. makes pharmaceutical intermediates and APIs to order. We also develop processes, transfer technology and run capacity expansion for pharma CROs and drug companies in China and overseas.

We don't stop at a lab report. The pilot plant, the hydrogenation platform, the production hall and the QC lab are all ours. When a route leaves the bench, someone here picks it up: scale it, validate it, deliver it, run it again.

  • 75+Projects in the past year
  • 12Commercialised products
  • 78%Repeat customer rate
  • 20+Process packages per year

02 Capabilities

Four stages, joined up in one place.

Projects usually stall for one of two reasons: the group that developed the route can't scale it, or the plant that can scale it won't rework the route. We keep those stages under one roof.

01

Process development

Route screening, condition optimisation, impurity control. We work out yield, waste load and safety margins before deciding whether the route is worth scaling.

02

Pilot scale-up

Fourteen reactors across 200 L, 300 L and 500 L lines, from −70 °C to 200 °C. Built for validating what came off the bench, and for small-lot custom orders.

03

Technology transfer

Process description, mass balance, equipment matching, SOPs and batch records. What you get is documentation that reproduces — not just one shipment.

04

Commercial manufacturing

Glass-lined 8,000 / 5,000 / 2,000 L and stainless 5,000 / 3,000 / 2,000 L. Orders from 100 kg up to multi-tonne.

05

Wide chemistry range

Thirteen reaction types, seven of them hazardous processes under national supervision — hydrogenation, nitration, chlorination, oxidation, amination, alkylation, diazotisation. Site, equipment and operating experience are all in-house.

06

Custom synthesis

From grams to hundreds of kilograms, toll or custom. We can run your route, or rework it.

03 Chemistry

More chemistry than you'd expect.

Thirteen reaction classes in total, seven of them hazardous processes under national supervision. Hydrogenation and nitration are the ones many CDMOs decline. We have separate dedicated areas, purpose-built equipment, and people who have actually run them.

Chemistry outside this list can still be assessed for feasibility, at no charge.

Hazardous processes7

  • Hydrogenationlow / medium pressure
  • Chlorination
  • Oxidation
  • Amination
  • Alkylation
  • Nitration
  • Diazotisation

Other chemistry6

  • Low / medium pressure synthesis
  • Catalytic coupling
  • Chiral centre inversion
  • Chiral resolution
  • Transaminase biocatalysis
  • Protecting-group chemistry

04 Capacity & equipment

Three stages, three order sizes.

The pilot plant validates. The hydrogenation platform takes the high-pressure work. The production hall delivers. One site, one quality system.

Zhonghongda pilot plant: stainless steel and glass-lined 200 L, 300 L and 500 L reactors

Pilot plant

Where a bench result becomes a batch you can repeat.

Reactors
200 / 300 / 500 L, 14 units
Material
Stainless steel / glass-lined
Temperature
−70 °C to 200 °C (TCU)
Purpose
Scale-up validation · small lots
Zhonghongda hydrogenation platform: five 3,000 L hydrogenators in an open external structure

Hydrogenation platform

Open external structure, built for high-pressure hydrogen work.

Hydrogenators
3,000 L × 5
Medium pressure
SS, 2 units, ~3.5 MPa
Medium-high
SS, 3 units, ~7.5 MPa
High temp / pressure
5,000 L × 1, 200 °C / ~9.5 MPa
Zhonghongda production hall: operators working on site
Production hall · three-level vertical flow, material never backtracks

Production hall · main reactors

Production reactor list
ReactorMaterialVolumeNote
Reactor 01Glass-lined8,000 LCapacity ceiling
Reactor 02Glass-lined5,000 L—
Reactor 03Glass-lined2,000 L—
Reactor 04Stainless steel5,000 L—
Reactor 05Stainless steel3,000 L—
Reactor 06Stainless steel2,000 L—

Drying room with double-cone rotary dryers and a clean packaging room sit downstream of the reactors.

05 Quality & R&D

Every claim has data behind it.

The QC lab reports independently of production. It covers incoming material, in-process control and release. On the R&D side we run joint laboratories with two universities, so there is somewhere to ask when a route gets stuck.

HPLC
Agilent 1260 × 3 · 1100 × 6
GC
Agilent 8860 × 1 · 7820A × 3
R&D team
13 people
Process packages
20+ per year
Zhonghongda QC laboratory: HPLC and GC instruments
QC laboratory · HPLC and GC

University partnerships

Joint laboratories with Shandong University and Beijing University of Chemical Technology. We bring their method-development capability into live projects, and we recruit through the same channel.

06 Project records

Three projects, as they happened.

Customer names omitted. The process steps are as they were. Different materials, different blocking points, different fixes.

Case 01

Scaling an aggressive material

An API intermediate whose route needed a strongly irritant material. On the bench it was done by two or three people in respirators taking turns at the addition — about ten minutes each, then out and swap.

At scale, both the addition time and the exposure risk went up. That was the blocking point when the project came to us. We didn't touch the reaction first. We re-laid the area: how the material is decanted, moved and charged, turning an open procedure into a controlled one.

Addition time came down, and the product went from grams to tonnes.

Scalegrams → tonnes

Changeddecant / transfer / charging / PPE

Case 02

p-Xylene side-chain chlorination · reactive distillation

A scale-up project for a p-xylene side-chain chlorination intermediate. Both methyl groups are chlorinated at 120 °C with chlorine gas, one chlorine each. Radical chlorination proceeds stepwise — a little too hot and it overruns, converting one methyl all the way to the di- and tri-chloro by-products. On the bench the tri-chloro fraction stayed low; once the pilot batch was scaled, impurities scaled with it and the product could not meet the client's in-house specification.

The usual approach is to react, discharge, work up, then run a separate distillation column — two separation steps, high energy, high losses. We combined reaction and distillation into a single reactive distillation column, so the product is removed as it forms and over-chlorination is suppressed inside the column.

Temperature and light were fixed as the critical parameters. The dichloro content now releases consistently against the client's specification, batch to batch.

Conditionschlorine gas · 120 °C · photoinitiated

Changedreactive distillation · online column T/P monitoring

Case 03

Tolvaptan intermediate · impurity control in a reduction step

A carbonyl reduction in a tolvaptan intermediate, using KBH4 in methanol. The problem was not yield but impurity: raise the temperature and side reactions follow. The client's in-house limit for this step is 0.1%, and with conventional single-shot charging the pilot batches drifted noticeably — two of them ran close to the line.

We locked the temperature across the whole step to 0–10 °C as a hard process limit, not to be exceeded. KBH4 is charged in portions at set intervals with the charge decreasing batch by batch, the reaction is tracked by HPLC throughout, and work-up was tightened at the same time.

The impurity now sits consistently below 0.05%, roughly half the client's limit.

Impurity0.1% → below 0.05%

Changed0–10 °C hard limit · staged interval charging

Customer names are withheld under confidentiality. Process details have been limited to what can be published.

07 Products

In-house and in production.

12 commercialised products, single-step yield above 90%, impurity profiles within ICH-Q3A. Main products and intermediates below — quote by CAS number.

API Active substances

  • Fendizoic acid芬地柞酸84627-04-3
  • Clofazimine氯苯吩嗪2030-63-9
  • Moxonidine莫索尼定75438-57-2

Moxonidine intermediates 莫索尼定

  • 4,6-Dichloro-2-methyl-5-(1-acetyl-2-imidazolin-2-yl)aminopyrimidine75438-54-9
  • N-Acetyl-2-imidazolidinone5391-39-9
  • 5-Amino-2,4-dichloro-6-methylpyrimidine39906-05-2

Olmesartan intermediates 奥美沙坦

  • Diethyl oxalacetate sodium salt40876-98-0
  • Diethyl oxalacetate108-56-5
  • Ethyl 5-oxo-4,5-dihydroisoxazole-3-carboxylate70432-25-6

Formoterol intermediates 福莫特罗

  • 3'-Nitro-4'-benzyloxy-2-bromoacetophenone43229-01-2
  • (1R,2S)-1-Amino-2-indanol136030-00-7

Regorafenib intermediates 瑞戈非尼

  • 3-Fluoro-4-nitrophenol394-41-2
  • 3-Fluoro-4-aminophenol399-95-1
  • 4-(3-Fluoro-4-nitrophenoxy)-N-methylpyridine-2-carboxamide1807470-57-0
  • 4-(4-Amino-3-fluorophenoxy)pyridine-2-carboxamide757251-39-1

Pazopanib intermediates 帕唑帕尼

  • 3-Amino-6-methylbenzenesulfonamide6973-09-7
  • 2,4-Dichloropyrimidine3934-20-1
  • 6-Amino-2,3-dimethyl-2H-indazole444731-72-0
  • 2,3-Dimethyl-6-nitro-2H-indazole444731-73-1

VEGFR-2 inhibitor intermediates

  • 6-Hydroxy-1-naphthoic acid2437-17-4
  • Methyl 6-(trifluoromethylsulfonyloxy)-1-naphthoate255050-65-8

Other intermediates

  • 6-Chlorooxindole ziprasidone56341-37-8
  • 1-(Pyridin-4-yl)propan-2-one milrinone6304-16-1
  • Ethyl 2-methoxyacetoacetate cilnidipine22502-03-0
  • Bis(2-chloroethyl)carbamoyl chloride estramustine2998-56-3

Oligonucleotide synthesis reagents 核苷酸合成试剂≥ 98% · water ≤ 0.2% · 100 g–50 kg

  • 5-Ethylthio-1H-tetrazole ETT activator89797-68-2
  • 5-Benzylthio-1H-tetrazole BTT activator21871-47-6
  • 4,5-Dicyanoimidazole DCI activator1122-28-7
  • Phenylacetyl disulfide PADS sulfurising reagent15088-78-5
  • ADTT sulfurising reagent6846-35-1

Custom synthesis beyond the catalogue. Send us the structure and we will assess feasibility first.

08 How we work

One project, one team of three.

Every customer is handled by an account manager, a technical lead and a commercial contact, backed by six functions: process R&D, analytical and QC, technology transfer, production, quality/EHS, and chemical engineering.

Technical lead

Owns the process

Route, parameters and scale-up plan are followed by one person from start to finish. No handover, no changed story, no data starting over.

Commercial contact

Owns the communication

Quotation, contract, NDA, reconciliation — one sentence, clearly, without passing it back and forth.

Three people on the project, six functions behind them — not a line where sales takes the order and technical carries the blame.

Model 01

Process development

You have the target molecule. We have the route and the line.

  • Route screening and feasibility
  • Bench route and condition optimisation
  • Impurity profile and analytical methods
  • Stage-gated payment, milestone acceptance

Model 03

Technology transfer and expansion

Your process needs to move. We land it.

  • Process documentation and equipment matching
  • Three-batch validation and release support
  • Operator training and on-site support
  • Long-term capacity agreements
  1. 1

    Scoping

    Substrate, target product, quantity, timeline. NDA first if structures are involved.

    Reply within one working day

  2. 2

    Route assessment

    Proposed route, risk points, lead time and cost, with the deliverables listed.

    3–5 working days

  3. 3

    Bench confirmation

    Route proven, qualified sample and key data in hand. Scale-up starts only after both sides sign off.

    Stage-gated acceptance

  4. 4

    Pilot scale-up

    Stepwise scale-up with mass and heat balance at each stage, critical parameters recorded.

    200 L → 500 L → production

  5. 5

    Delivery and handover

    Product, process package and batch records delivered, with support for the first commercial campaign.

    Three-batch validation included

09 Contact

Send the structure.
We'll tell you if we can make it.

Tell us the substrate, the target product, the quantity and the timeline. What you get back: whether we can run it, which route, roughly how long, and where the risks sit.

  • ContactHaowei Yang
  • Phone / WeChat+86 173 1443 7686
  • Emailyang_haowei@zhd-pharma.cn
  • AddressBuilding A3, Juzhi Park, No. 3 Kehui Road, Pukou District, Nanjing, Jiangsu, China
  • HoursMon–Fri, 9:00–18:00 (GMT+8)

This opens your email client. You can also write to us directly — usually faster.